Peter Van Loo, Ph.D.
Department of Genetics, Division of Discovery Science
About Peter Van Loo
Dr. Van Loo is a professor and CPRIT scholar at the University of Texas MD Anderson Cancer Center, Department of Genetics, with a joint appointment at the Department of Genomic Medicine. His research focuses on leveraging massively parallel sequencing efforts to study the evolutionary history of cancers. During his postdoctoral training, Dr. Van Loo developed computational techniques to study copy-number alterations in cancer genomes, and approaches to study the evolutionary history and subclonal architecture of tumors from whole-genome sequencing data, a field coined “molecular archeology of cancer”. As an independent researcher, first as a Group Leader at the Francis Crick Institute in London, UK, and later as a professor at the University of Texas MD Anderson Cancer Center, Dr. Van Loo has sketched the typical evolutionary trajectories of many cancer types, allowing insight into the timelines of cancer development, as well as insight into how tumors metastasize. He was the main lead of Evolution and Heterogeneity working group of the Pan-Cancer Analysis of Whole Genomics (PCAWG) Consortium, and am the genomics lead of the Sarcoma arm of the 100,000 Genomes Project.
In recognition of his work, Dr. Van Loo has been awarded a Cancer Research UK Future Leaders in Cancer Research Prize in 2015, a VIB Alumni Award in 2017, and a UT STARs award in 2022. He co-authored 138 publications in international journals, including Nature (15), Science (5), Cell (7), New England Journal of Medicine (3), Nature Genetics (11), Cancer Cell (5), Nature Medicine (2) and Nature Biotechnology (7). These have accumulated 35,095 citations (H-index: 68).
View a complete list of Dr. Van Loo's publications. Visit Dr. Van Loo’s Lab website. Follow Dr. Van Loo on Twitter: @VanLooLab View Dr. Van Loo’s publication highlights as reflected in Elsevier’s Scopus database.
Present Title & Affiliation
Primary Appointment
Professor, Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Cancer Genomics and Evolution – Molecular archeology of cancer
Our group has pioneered molecular archeology of cancer approaches to study the evolutionary history and subclonal architecture of tumors. These approaches have significantly advanced our understanding of how cancer develops and evolves, how metastatic cancer spreads, and how resistance to therapy emerges. We use these existing molecular archeology of cancer approaches and develop novel ones, to perform large-scale pan-cancer studies of tumor evolution, as well as focused studies in specific tumor types, aiming to answer the key question: How do tumors evolve?
View a complete list of Dr. Van Loo's publications. Visit Dr. Van Loo’s Lab website. Follow Dr. Van Loo on Twitter: @VanLooLab View Dr. Van Loo’s publication highlights as reflected in Elsevier’s Scopus database.
Education & Training
Degree-Granting Education
| 2008 | University of Leuven, Leuven, BEL, PHD, Medical Sciences |
| 2004 | University of Leuven, Leuven, BEL, MS, Cell- and Gene Biotechnology |
| 2003 | University of Leuven, Leuven, BEL, MS, Electrotechnical Engineering |
Postgraduate Training
| 2010-2014 | Postdoctoral Researcher, Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton Cambridge |
| 2008-2010 | Postdoctoral Researcher, Human Genome Laboratory, VIB and University of Leuven, Leuven |
| 2008-2008 | Postdoctoral Researcher, Institute for Cancer Research, University of Oslo, Oslo |
Experience & Service
Academic Appointments
Assistant Professor (10% appointment), University of Leuven, Leuven, 2013 - 2019
Honors & Awards
| 2015 | Cancer Research UK Future Leaders in Cancer Research Prize |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Megyesfalvi Z, Heeke S, Drapkin BJ, Solta A, Kovacs I, Boettiger K, Horvath L, Ernhofer B, Fillinger J, Renyi-Vamos F, Aigner C, Schelch K, Lang C, Marko-Varga G, Gay CM, Byers LA, Morris BB, Heymach JV, Van Loo P, Hirsch FR, Dome B. Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsies. Cancer Cell 41(9):1535-1540, 2023. PMID: 37699331.
- O'Connor D, Demeulemeester J, Conde L, Kirkwood A, Fung K, Papaleonidopoulou F, Bloye G, Farah N, Rahman S, Hancock J, Bateman C, Inglott S, Mee J, Herrero J, Van Loo P, Moorman AV, Vora A, Mansour MR. The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol 41(19):3545-3556, 2023. e-Pub 2023. PMID: 37098241.
- Karasaki T, Moore DA, Veeriah S, Naceur-Lombardelli C, Toncheva A, Magno N, Ward S, Bakir MA, Watkins TBK, Grigoriadis K, Huebner A, Hill MS, Frankell AM, Abbosh C, Puttick C, Zhai H, Gimeno-Valiente F, Saghafinia S, Kanu N, Dietzen M, Pich O, Lim EL, Martínez-Ruiz C, Black JRM, Biswas D, Campbell BB, Lee C, Colliver E, Enfield KSS, Hessey S, Hiley CT, Zaccaria S, Litchfield K, Birkbak NJ, Cadieux EL, Demeulemeester J, Van Loo P, Adusumilli PS, Tan KS, Cheema W, Sanchez-Vega F, Jones DR, Rekhtman N, Travis WD, Hackshaw A, Marafioti T, Salgado R, Le Quesne J, Nicholson AG, TRACERx Consortium, McGranahan N, Swanton C, Jamal-Hanjani M. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nat Med 29(4):833-845, 2023. e-Pub 2023. PMID: 37045996.
- Martínez-Ruiz C, Black JRM, Puttick C, Hill MS, Demeulemeester J, Larose Cadieux E, Thol K, Jones TP, Veeriah S, Naceur-Lombardelli C, Toncheva A, Prymas P, Rowan A, Ward S, Cubitt L, Athanasopoulou F, Pich O, Karasaki T, Moore DA, Salgado R, Colliver E, Castignani C, Dietzen M, Huebner A, Al Bakir M, Tanic M, Watkins TBK, Lim EL, Al-Rashed AM, Lang D, Clements J, Cook DE, Rosenthal R, Wilson GA, Frankell AM, de Carné Trécesson S, East P, Kanu N, Litchfield K, Birkbak NJ, Hackshaw A, Beck S, Van Loo P, Jamal-Hanjani M, TRACERx Consortium, Swanton C, McGranahan N. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature 616(7957):543-552, 2023. e-Pub 2023. PMID: 37046093.
- Al Bakir M, Huebner A, Martínez-Ruiz C, Grigoriadis K, Watkins TBK, Pich O, Moore DA, Veeriah S, Ward S, Laycock J, Johnson D, Rowan A, Razaq M, Akther M, Naceur-Lombardelli C, Prymas P, Toncheva A, Hessey S, Dietzen M, Colliver E, Frankell AM, Bunkum A, Lim EL, Karasaki T, Abbosh C, Hiley CT, Hill MS, Cook DE, Wilson GA, Salgado R, Nye E, Stone RK, Fennell DA, Price G, Kerr KM, Naidu B, Middleton G, Summers Y, Lindsay CR, Blackhall FH, Cave J, Blyth KG, Nair A, Ahmed A, Taylor MN, Procter AJ, Falzon M, Lawrence D, Navani N, Thakrar RM, Janes SM, Papadatos-Pastos D, Forster MD, Lee SM, Ahmad T, Quezada SA, Peggs KS, Van Loo P, Dive C, Hackshaw A, Birkbak NJ, Zaccaria S, TRACERx Consortium, Jamal-Hanjani M, McGranahan N, Swanton C. The evolution of non-small cell lung cancer metastases in TRACERx. Nature 616(7957):534-542, 2023. e-Pub 2023. PMID: 37046095.
- Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, Veeriah S, Colliver E, Huebner A, Bunkum A, Hill MS, Grigoriadis K, Moore DA, Black JRM, Liu WK, Thol K, Pich O, Watkins TBK, Naceur-Lombardelli C, Cook DE, Salgado R, Wilson GA, Bailey C, Angelova M, Bentham R, Martínez-Ruiz C, Abbosh C, Nicholson AG, Le Quesne J, Biswas D, Rosenthal R, Puttick C, Hessey S, Lee C, Prymas P, Toncheva A, Smith J, Xing W, Nicod J, Price G, Kerr KM, Naidu B, Middleton G, Blyth KG, Fennell DA, Forster MD, Lee SM, Falzon M, Hewish M, Shackcloth MJ, Lim E, Benafif S, Russell P, Boleti E, Krebs MG, Lester JF, Papadatos-Pastos D, Ahmad T, Thakrar RM, Lawrence D, Navani N, Janes SM, Dive C, Blackhall FH, Summers Y, Cave J, Marafioti T, Herrero J, Quezada SA, Peggs KS, Schwarz RF, Van Loo P, Miedema DM, Birkbak NJ, Hiley CT, Hackshaw A, Zaccaria S, TRACERx Consortium, Jamal-Hanjani M, McGranahan N, Swanton C. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature 616(7957):525-533, 2023. e-Pub 2023. PMID: 37046096.
- Birkeälv S, Harland M, Matsuyama LSAS, Rashid M, Mehta I, Laye JP, Haase K, Mell T, Iyer V, Robles-Espinoza CD, McDermott U, van Loo P, Kuijjer ML, Possik PA, Maria Engler SS, Bishop DT, Newton-Bishop J, Adams DJ. Mutually exclusive genetic interactions and gene essentiality shape the genomic landscape of primary melanoma. J Pathol 259(1):56-68, 2023. e-Pub 2022. PMID: 36219477.
- Ottina E, Panova V, Doglio L, Kazachenka A, Cornish G, Kirkpatrick J, Attig J, Young GR, Litchfield K, Lesluyes T, Van Loo P, Swanton C, MacRae J, Tüting T, Kassiotis G. E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion. Oncogene 40(37):5567-5578, 2021. e-Pub 2021. PMID: 34145398.
- Ross EM, Haase K, Van Loo P, Markowetz F. Allele-specific multi-sample copy number segmentation in ASCAT. Bioinformatics 37(13):1909-1911, 2021. PMID: 32449758.
- Dentro SC, Leshchiner I, Haase K, Tarabichi M, Wintersinger J, Deshwar AG, Yu K, Rubanova Y, Macintyre G, Demeulemeester J, Vázquez-García I, Kleinheinz K, Livitz DG, Malikic S, Donmez N, Sengupta S, Anur P, Jolly C, Cmero M, Rosebrock D, Schumacher SE, Fan Y, Fittall M, Drews RM, Yao X, Watkins TBK, Lee J, Schlesner M, Zhu H, Adams DJ, McGranahan N, Swanton C, Getz G, Boutros PC, Imielinski M, Beroukhim R, Sahinalp SC, Ji Y, Peifer M, Martincorena I, Markowetz F, Mustonen V, Yuan K, Gerstung M, Spellman PT, Wang W, Morris QD, Wedge DC, Van Loo P, PCAWG Evolution and Heterogeneity Working Group and the PCAWG Consortium. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell 184(8):2239-2254.e39, 2021. e-Pub 2021. PMID: 33831375.
- Minussi DC, Nicholson MD, Ye H, Davis A, Wang K, Baker T, Tarabichi M, Sei E, Du H, Rabbani M, Peng C, Hu M, Bai S, Lin YW, Schalck A, Multani A, Ma J, McDonald TO, Casasent A, Barrera A, Chen H, Lim B, Arun B, Meric-Bernstam F, Van Loo P, Michor F, Navin NE. Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature 592(7853):302-308, 2021. e-Pub 2021. PMID: 33762732.
- Chatsirisupachai K, Lesluyes T, Paraoan L, Van Loo P, de Magalhães JP. An integrative analysis of the age-associated multi-omic landscape across cancers. Nat Commun 12(1):2345, 2021. e-Pub 2021. PMID: 33879792.
- Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, Watkins TBK, Rosenthal R, Biswas D, Rowan A, Lim E, Al Bakir M, Turati V, Guerra-Assunção JA, Conde L, Furness AJS, Saini SK, Hadrup SR, Herrero J, Lee SH, Van Loo P, Enver T, Larkin J, Hellmann MD, Turajlic S, Quezada SA, McGranahan N, Swanton C. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184(3):596-614.e14, 2021. e-Pub 2021. PMID: 33508232.
Other Articles
- Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton JD, Curbishley SM, Dong T, Dustin ML, Hu Z, McGranahan N, Miller ML, Santana-Gonzalez L, Seymour LW, Shi T, Van Loo P, Yau C, White H, Wietek N, Church DN, Wedge DC, Ahmed AA Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer 124(11):1759-1776, 2021. PMID: 33782566.
- Tarabichi M, Salcedo A, Deshwar AG, Ni Leathlobhair M, Wintersinger J, Wedge DC, Van Loo P, Morris QD, Boutros PC A practical guide to cancer subclonal reconstruction from DNA sequencing. Nat Methods 18(2):144-155, 2021. PMID: 33398189.
Grant & Contract Support
| Title: | Recruitment of Established Investigators - Dr. Peter Van Loo |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator |
| Title: | Characterizing the somatic genomic landscape of malignant peripheral nerve sheath tumours at single-cell and single-molecule resolution |
| Funding Source: | NF Research Initiative |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified December 04, 2024